论文部分内容阅读
目的探讨KAI1/CD82在神经母细胞瘤转移中的表达及意义。方法选取40例各期神经母细胞瘤、9例节细胞神经瘤蜡块标本,应用免疫组织化学方法检测KAI1基因的蛋白产物CD82的表达水平。结果无转移组中的CD82的阳性率为71.43%,有淋巴结或远处转移的其阳性率为34.74%,节细胞神经瘤中CD82的表达阳性率为22.22%,有或无转移的神经母细胞瘤组之间及无转移的神经母细胞瘤和节细胞神经瘤组之间的差异有统计学意义,神经母细胞瘤中KAI1/CD82的表达水平与是否转移有相关性,与是否进行过化疗无关,与转移为其他器官或骨髓也无相关性。结论KAI1/CD82的表达水平与神经母细胞瘤的转移潜能呈负相关。
Objective To investigate the expression of KAI1 / CD82 in neuroblastoma and its significance. Methods 40 cases of neuroblastoma and 9 cases of neuroblastoma were selected for immunohistochemistry. The expression of KAI1 protein CD82 was detected by immunohistochemistry. Results The positive rate of CD82 in non-metastasis group was 71.43%, the positive rate in lymph node or distant metastasis was 34.74%, the positive rate of CD82 expression in ganglioneuroma was 22.22%, with or without metastasis The difference between the tumor group and the non-metastatic neuroblastoma and ganglioneuroma group was statistically significant. The expression of KAI1 / CD82 in neuroblastoma was correlated with the metastasis and with or without chemotherapy Has nothing to do with the transfer of other organs or bone marrow also has no relevance. Conclusion The expression of KAI1 / CD82 is negatively correlated with the metastatic potential of neuroblastoma.